Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance) Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Bevacizumab
  • Breast Neoplasms
  • Nitriles
  • Postmenopause
  • Triazoles

abstract

  • The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting.

publication date

  • August 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5012690

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.66.1595

PubMed ID

  • 27138575

Additional Document Info

start page

  • 2602

end page

  • 9

volume

  • 34

number

  • 22